Correction: IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma

Oncogene. 2023 Mar;42(11):858. doi: 10.1038/s41388-023-02607-8.

Dawei Song¹, Sonia Cismas¹, Caitrin Crudden^{1

2}, Eric Trocme^{1

3}, Claire Worrall¹, Naida Suleymanova¹, Tingting Lin^{1

4}, Huiyuan Zheng^{1

5}, Stefan Seregard^{3

6}, Ada Girnita^{1

7}, Leonard Girnita^{8

9}

¹ Department of Oncology and Pathology, BioClinicum, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
² Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands.
³ Ophthalmic Pathology and Oncology Service, St. Erik Eye Hospital, Stockholm, Sweden.
⁴ Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
⁵ Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
⁶ Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
⁷ Skin Cancer Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
⁸ Department of Oncology and Pathology, BioClinicum, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. leonard.girnita@ki.se.
⁹ Ophthalmic Pathology and Oncology Service, St. Erik Eye Hospital, Stockholm, Sweden. leonard.girnita@ki.se.

No abstract available

Publication types